Sugi Predict

Sugi Predict / Compounds / SCHEMBL763349

SCHEMBL763349

SCHEMBL763349

Cc1cccc2[nH]c(=O)[nH]c12

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GRIA1 P42261 2/20 0.52
▸ CACNG8 Q8WXS5 2/20 0.52
▸ KIF11 P52732 1/20 0.50
▸ PDE3B Q13370 3/20 0.47
▸ PDE3A Q14432 3/20 0.47
▸ DAO P14920 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ CA12 O43570 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ DDO Q99489 2/20 0.43
▸ AHR P35869 1/20 0.42
▸ CHEK1 O14757 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ TNKS2 Q9H2K2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419187 0.82 GRIN2D (0.54) KIF11DAOKDM4EDDOCHEK1
SCHEMBL4560641 0.78 KDM4E (0.46) GRIA1CACNG8PDE3BPDE3ADAO
SCHEMBL11385706 0.77 KDM4E (0.43) GRIA1CACNG8PDE3BPDE3AKDM4E
SCHEMBL3125353 0.77 PARP1 (0.49) GRIA1CACNG8PDE3BPDE3ADAO
SCHEMBL5379137 0.77 DAO (0.46) PDE3BPDE3ADAOKDM4ECA12
SCHEMBL2919116 0.77 CHEK1 (0.53) KIF11DAOKDM4ECA12PARP1
SCHEMBL30013759 0.77 PARP1 (0.49) GRIA1CACNG8PDE3BPDE3ADAO
SCHEMBL6367421 0.76 KDM4E (0.42) GRIA1CACNG8PDE3BPDE3AKDM4E
SCHEMBL22619216 0.76 KDM4E (0.42) PDE3BPDE3AKDM4ECA12PARP1
SCHEMBL2483323 0.76 POLB (0.52) GRIA1CACNG8PDE3BPDE3AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2501236-B1 N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer PLEXXIKON INC (US) 2017-03-29 — — EP claimed
US-8673928-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2014-03-18 — — US claimed
EP-2501236-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2012-09-26 — — EP claimed
US-20110152258-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON INC. 2011-06-23 — — US claimed
WO-2011063159-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-26 — — WO claimed
JP-6065164-A — — None — — JP disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 — — US disclosed
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-10-26 — — US disclosed
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-10-26 — — US disclosed
WO-2023183585-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2023-09-28 — — WO disclosed
US-20230227472-A1 FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) 2023-07-20 — — US disclosed
US-20230227472-A1 FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) 2023-07-20 — — US disclosed
EP-1386920-A1 BENZIMIDAZOLONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-02-04 — — EP disclosed
CN-1386738-A Process for synthesizing benzimidazolone and its derivatives DALIAN CHEMICAL PHYSICS INST (CN) 2002-12-25 — — CN disclosed
EP-1221443-A1 SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-07-10 — — EP disclosed
US-5436240-A Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines THE UPJOHN COMPANY (US) 1995-07-25 — — US disclosed
EP-0480939-B1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY UPJOHN CO (US) 1995-01-25 — — EP disclosed
JP-H0665164-A PRODUCTION OF CYCLOHEXANE-1,2-DIAMINES MITSUI TOATSU CHEM INC 1994-03-08 — — JP disclosed
US-5273975-A Heterocyclic amines having central nervous system activity THE UPJOHN COMPANY (US) 1993-12-28 — — US disclosed
WO-1990015058-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY THE UPJOHN COMPANY (US) 1990-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL GRIA1 344/4885CACNG8 4248/4885KIF11 3586/4885
US-20110152258-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, KRAS, RAF1 GRIA1 1314/4885CACNG8 2576/4885KIF11 627/4885
US-20230227472-A1 FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, WEE1 GRIA1 1557/4885CACNG8 3303/4885KIF11 262/4885
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF PTPRF, PTPRCAP, PTPRJ GRIA1 1392/4885CACNG8 2403/4885KIF11 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.